First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
03 janv. 2019 07h30 HE
|
Biogen Inc.
Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- The first patient has been...
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
17 déc. 2018 07h30 HE
|
Biogen Inc.; Alkermes plc
DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application...
First Descents Expands Programming to Serve Young Adults with Multiple Sclerosis
25 oct. 2018 09h00 HE
|
Velocity Global
Denver, CO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- After 17 years of helping to improve the lives of young adults with cancer through activities like kayaking, rock climbing and surfing, non-profit First...
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
11 oct. 2018 07h30 HE
|
Biogen Inc.
Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood testReal-world data add to the...
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
03 oct. 2018 09h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline targeting endocannabinoid...
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
02 oct. 2018 07h30 HE
|
Biogen Inc.
New research further supports the long-term efficacy and well-characterized safety of leading MS productsNovel data generation initiatives aim to improve outcomes and support the continued move toward...
Q Therapeutics Receives Orphan Drug Designation for Transverse Myelitis
26 sept. 2018 06h00 HE
|
Q Therapeutics, Inc.
FDA DESIGNATION WOULD PROVIDE 7 YEARS OF MARKET EXCLUSIVITY UPON MARKET APPROVAL OF Q-CELLS® SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage...
Aphios Pharma LLC Announces Reg. CF Private Placement Offering
17 sept. 2018 08h00 HE
|
Aphios
WOBURN, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aphios® Pharma LLC is pleased to announce the launch of a private placement offering in accordance with Regulation Crowdfunding (Reg. CF) adopted...
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
15 août 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
Adamas Reports Second Quarter 2018 Financial Results
02 août 2018 16h01 HE
|
Adamas Pharmaceuticals, Inc.
- GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter - EMERYVILLE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....